ong-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in IPF

Central Japan Lung Study Grou0 sites84 target enrollmentMarch 3, 2017

Overview

No summary available.

Registry

who.int

Start Date

March 3, 2017

End Date

December 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Central Japan Lung Study Grou

•1\)Patients with connective tissue disease, known neuromuscular disease or other orthopedic problem which may affect to exercise assessment, other disease requires exercise limitation 2\)Patients who received pulmonary rehabilitation within 12 months 3\)Patients with oral corticosteroids \>15mg/day (prednisolone equivalent) or immunosuppressive agents within 3 months 4\)Patients with pirfenidone within 3 months 5\)Patients with unstable angina, a history of myocardial infarction or received percutaneous transluminal coronary angioplasty or coronary\-artery bypass surgery within 1 month or a history of a cerebrovascular disease within 6 months. 6\)Patients who requires antiarrhythmic therapy 7\)Patients with serious pulmonary hypertension 8\)ALT or AST \> 2x upper limit of normal 9\)Total bilirubin \> 2x upper limit of normal 10\)Creatinine clearance \< 30mL/min 11\)Patients who require fibrinolysis, full\-dose therapeutic anticoagulation (e.g. vitamin K antagonists, direct thrombin inhibitors, heparin, hirudin) or high dose antiplatelet therapy. 12\)Pregnant women and women of possibly pregnant. 13\)Patients who cannot be evaluated by 6 minute walk test for any reason. 14\)Other patients who are judged by the investigator as not adequate to participate in the study. 15\)History of malignant disease within 3 years.